Masterclass: Beyond Current Biologics: Exploring Novel Strategies in Hidradenitis Suppurativa

Hidradenitis suppurativa is a chronic inflammatory skin disease that often goes unrecognized, leading to delayed diagnosis and significant patient burden. This session reviews the pathogenesis of HS, strategies for early identification, and approaches to individualized treatment. Faculty will discuss current biologic therapies alongside emerging data on oral JAK inhibitors and their potential role in disease management. Attendees will gain practical guidance on treatment selection, sequencing, and optimizing long-term outcomes for patients with HS.

Learning Objectives

• Recognize the clinical presentations, high-risk features, and consequences of delayed diagnosis in HS to support timely, evidence-based intervention and prevent disease progression
• Explain the role of the JAK/STAT signaling pathway in HS pathogenesis and describe the mechanisms by which oral JAK1 inhibitors may modulate disease activity
• Evaluate the efficacy and safety data for biologic therapies and oral JAK inhibitors in HS to inform individualized treatment selection
• Apply evidence-based treatment strategies for patients with moderate-to-severe HS, incorporating patient preferences, comorbidities, prior treatment response, and practical considerations into shared decision-making

Supported by an educational grant from Incyte Corporation.